HANSOH PHARMA'S INNOVATIVE DRUG FLUMATINIB FOR NEWLY DIAGNOSED ADULT PH+ ALL FEATURED AT INTERNATIONAL ACADEMIC CONFERENCE
The European Society for Medical Oncology (ESMO) Congress 2024 was held in Barcelona, Spain, from September 13 to 17 (local time). Hansoh Pharma's innovative drug Flumatinib was showcased at the conference in the form of a poster presentation. Led by Professors Wang Weimin and Sun Hui from the First Affiliated Hospital of Zhengzhou University, the study evaluated the efficacy of Flumatinib combined with multi-drug chemotherapy as a first-line treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The finding offers new evidence-based support for the use of Flumatinib in treating Ph+ ALL.
Flumatinib is China's first domestically developed second-generation TKI for chronic myeloid leukemia (CML). It has shown promising efficacy and good tolerability in multiple clinical studies on CML and has demonstrated considerable potential in treating Ph+ ALL as well.
Ph+ ALL accounts for 20% to 30% of adult acute lymphoblastic leukemia (ALL) cases, with poor outcomes using traditional chemotherapy. The five-year survival rate with multi-drug chemotherapy is less than 20%. However, the introduction of tyrosine kinase inhibitors (TKIs) in first-line treatment has significantly improved the prognosis for Ph+ ALL patients.
Background: Outcomes in patients with Philadelphia chromosome positive (Ph+) acute lympho blastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors(TKIs).
Methods: This was a single-center, retrospective observational study conducted on patients with newly diagnosed Ph+ ALL patients who received flumatinib combined with multiagent chemotherapy as treatment regimen between April 2020 to May 2023. Patients were followed up by electronic medical record system and by telephone until 14 November 2023.
Results: After the administration of flumatinib combined with multiagent chemotherapy, the induced complete remission (CR), 3 month CR, and 6 month CR rates achieved 97.9%, 100%, and 93.3%, respectively. The rate of minimal residual disease negative (MRD-) by flow cytometry was 59.3%, 81.3%, 95.1%, and 90.0% in 0.5, 1, 3, and 6 months, respectively. The rates of major molecular response (MMR) were 54.6%, 61.4%, 82.0%, and 89.3% in 0.5, 1, 3, and 6 months after treatment, respectively. While the rates of complete molecular response (CMR) were 50.0%, 43.2%, 64.1%, and 85.7%.
With a median follow-up of 41.1 months, the 3 years overall survival (OS), progression-Free Survival (PFS) and event free survival (EFS) were 70.8%, 62.5% and 45.8%, respectively. 35.42% (17/48) patients were administered allogeneic SCT. The OS of patients with SCT was significantly better than patients without SCT (94.1% vs. 54.8%, p=0.0057). The OS of patients by CR after induction therapy significantly prolonged (70.21% vs. 0, p = 0.0001). The OS of patients with MRD-negative was remarkably better than patients MRD-positive (71.79% vs. 55.56%, p＜0.0001). The OS of patients whether they had achieved MMR and CMR suggested no impact on OS. 64.1%(25/39) patients received a CMR in 3 months after treatment, the OS of patients whether had achieved CMR revealed no statistical difference(68% vs. 78.57%, p=0.4618).
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
